Current role of beta-blockers in the treatment of hypertension
作者： Wilbert S Aronow
DOI: 10.1517/14656566.2010.482561
关键词:
摘要: Importance of the field: It is important to know which patients with hypertension will benefit from beta-blocker therapy and beta-blockers should be used in treatment reduce cardiovascular events mortality.Areas covered this review: Studies between 1981 2009 using a Medline search are reported. Beta-blockers treat previous myocardial infarction, acute coronary syndromes, angina pectoris, congestive heart failure, ventricular arrhythmias, supraventricular tachyarrhythmias, diabetes mellitus, after artery bypass graft surgery, who pregnant, have thyrotoxicosis, glaucoma, migraine, essential tremor, perioperative hypertension, or an excessive blood pressure response exercise.What reader gain: The use as first-line primary has been controversial. However, guidelines European Society Hypertension state that ...
informahealthcare.com参考文章(95)
Capricorn Investigators, Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. The Lancet. ,vol. 357, pp. 1385- 1390 ,(2001) , 10.1016/S0140-6736(00)04560-8
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) The Lancet. ,vol. 353, pp. 2001- 2007 ,(1999) , 10.1016/S0140-6736(99)04440-2
Sripal Bangalore, David Wild, Sanobar Parkar, Marrick Kukin, Franz H. Messerli, Beta-Blockers for Primary Prevention of Heart Failure in Patients With Hypertension Journal of the American College of Cardiology. ,vol. 52, pp. 1062- 1072 ,(2008) , 10.1016/J.JACC.2008.05.057
Donald E. Casey, Donna M. Mancini, Theodore G. Ganiats, Marvin A. Konstam, S Gary, Arthur M. Feldman, William T. Abraham, Heart and Lung Transplantation Developed in Collaboration With the International Society for Guidelines Cardiology Foundation/American Heart Association Task Force on Practice Management of Heart Failure in Adults: A Report of the American College of 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and ,(2009)
B Neal, Blood Pressure Lowering Treatment trialists Collaboration 15th European Society of Hypertension Annual Scientific Meeting. ,(2005)
, Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials The Lancet. ,vol. 362, pp. 1527- 1535 ,(2003) , 10.1016/S0140-6736(03)14739-3
Expert consensus document on beta-adrenergic receptor blockers. European Heart Journal. ,vol. 25, pp. 1341- 1362 ,(2004) , 10.1016/J.EHJ.2004.06.002
Aleksander Goch, Maciej Banach, Dimitri P. Mikhailidis, Jacek Rysz, Jan Henryk Goch, Endothelial Dysfunction in Patients with Noncomplicated and Complicated Hypertension Clinical and Experimental Hypertension. ,vol. 31, pp. 20- 30 ,(2009) , 10.1080/10641960802409846
JR Cockcroft, MJ Brown, Losartan for cardiovascular disease in patients with and without diabetes in the LIFE study The Lancet. ,vol. 359, pp. 2202- ,(2002) , 10.1016/S0140-6736(02)09075-X
George L Bakris, Vivian Fonseca, Richard E Katholi, Janet B McGill, Franz H Messerli, Robert A Phillips, Philip Raskin, Jackson T Wright, Rosemary Oakes, Mary Ann Lukas, Karen M Anderson, David SH Bell, for the GEMINI Investigators, Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. ,vol. 292, pp. 2227- 2236 ,(2004) , 10.1001/JAMA.292.18.2227